Sight Sciences, Inc. (SGHT) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights several positive developments: raised revenue guidance, reduced operating expenses, and significant market opportunities in the dry eye segment. Despite some cautious guidance and uncertainties in reimbursement and market access, the company's strategic focus and expected cost savings position it for growth. The Q&A session supports this with a generally positive sentiment from analysts, despite some vague responses from management. Overall, the positive aspects outweigh the negative, leading to a positive stock price outlook over the next two weeks.
Key Financial Performance
Total Revenue $20.4 million, a 7% increase year-over-year. The increase was driven by growth in both Interventional Glaucoma and Interventional Dry Eye segments.
Interventional Glaucoma Revenue $19.7 million, a 5% increase year-over-year. Growth was driven by increases in ordering accounts and higher average selling prices.
Interventional Dry Eye Revenue $0.7 million, up from $0.3 million year-over-year. The growth reflects positive traction in the reimbursed Interventional Dry Eye business model.
Gross Margin 87%, consistent with the prior year. Interventional Glaucoma gross margin was 88% (up from 87%) due to higher average selling prices and product mix, slightly offset by tariff costs. Interventional Dry Eye gross margin improved to 68% (up from 51%) due to higher average selling prices.
Total Operating Expenses $21.5 million, a decrease of 25% year-over-year. The decrease was primarily due to lower personnel-related expenses and stock-based compensation following a reduction in force in August 2025.
Adjusted Operating Expenses $18.9 million, a decrease of 23% year-over-year, reflecting the impact of the reduction in force and operational discipline.
Net Loss $4.2 million or $0.08 per share, compared to a net loss of $11.8 million or $0.23 per share year-over-year. The improvement reflects reduced operating expenses and operational discipline.
Cash and Cash Equivalents $92 million at the end of the quarter, compared to $120.4 million at the end of 2024. Cash usage was $0.4 million in the quarter, the lowest cash usage quarter of the year, reflecting operational discipline.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
OMNI and TearCare: Flagship interventional technologies addressing glaucoma and dry eye disease, respectively. These minimally invasive technologies aim to address the root causes of these diseases.
TearCare: Achieved a reimbursement milestone with pricing established for CPT code 0563T. Fourth-quarter revenue was $0.7 million, driven by sales of approximately 700 SmartLids to 80 accounts, including 30 new accounts.
OMNI: Fourth-quarter revenue was $19.7 million, up 5% year-over-year. Demonstrated importance in the glaucoma treatment paradigm despite market headwinds.
Interventional Dry Eye: Focused on pioneering the reimbursed Interventional Dry Eye treatment market. Investments are being made to strengthen provider engagement and expand commercialization in markets with established reimbursement.
Interventional Glaucoma: Strategy includes driving share gains, expanding the combo cataract segment, and developing the underpenetrated stand-alone market. Investments in commercial resources and pseudophakic market development are underway.
Revenue Growth: Total revenue for Q4 2025 was $20.4 million, a 7% increase year-over-year. Interventional Glaucoma revenue grew by 5%, and Interventional Dry Eye revenue more than doubled.
Cost Management: Operating expenses decreased by 25% year-over-year due to a reduction in force and lower personnel-related expenses. Adjusted operating expenses decreased by 23%.
Cash Management: Ended Q4 2025 with $92 million in cash and cash equivalents. Cash usage was $0.4 million in the quarter, the lowest of the year.
Rebranding: Renamed business segments to Interventional Glaucoma and Interventional Dry Eye to reflect a focus on procedure-based interventions.
Market Access: Deepening engagement with additional MACs and commercial payers to accelerate adoption and expand patient access.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Reimbursement Challenges: The company faces challenges in expanding market access and securing reimbursement for its Interventional Dry Eye procedures. While progress has been made with Novitas Solutions and First Coast Service Options, further engagement with additional MACs and commercial payers is critical for growth.
Market Growth Constraints in Glaucoma Segment: The Interventional Glaucoma segment experienced headwinds due to LCD changes restricting multiple MIGS procedures in combination with cataract surgery. This regulatory change has reduced the number of devices used, impacting market growth.
Dependence on Small Sales Team: The company’s small but growing sales team may limit its ability to scale and fully capitalize on market opportunities, particularly in the Interventional Dry Eye segment.
Economic and Financial Risks: The company reported a net loss of $4.2 million for the quarter and a decrease in cash and cash equivalents from $120.4 million to $92 million year-over-year. While operational discipline has reduced cash usage, financial constraints could impact future investments and growth.
Operational Scaling Challenges: Investments in commercial infrastructure and market development are necessary to scale the Interventional Dry Eye and Glaucoma segments. However, these investments could strain resources and delay profitability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2026: The company is initiating revenue guidance of $82 million to $88 million for 2026, reflecting growth of 6% to 14% compared to 2025. This includes $77 million to $81 million for the Interventional Glaucoma segment (growth of 2% to 7%) and $5 million to $7 million for the Interventional Dry Eye segment (compared to $1.6 million in 2025).
Interventional Glaucoma Segment Outlook: The company expects low single-digit growth in the first quarter of 2026 compared to the first quarter of 2025, with the first quarter being the lowest revenue quarter of the year. The second half of 2026 is expected to be higher than the first half.
Interventional Dry Eye Segment Outlook: Revenue is expected to be approximately $1 million in the first quarter of 2026, with revenue ramping throughout the year as the reimbursed TearCare launch expands and scales.
Adjusted Operating Expenses Guidance for 2026: The company expects full-year adjusted operating expenses to be $93 million to $96 million, representing an increase of 6% to 9% compared to 2025. The increase is driven by targeted market access and commercial investments in both Interventional Dry Eye and Interventional Glaucoma.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide some color on low-end versus high-end assumptions for guidance, specifically for Interventional Glaucoma and Interventional Dry Eye disease?
A:For Interventional Glaucoma, the market and reimbursement environment are more stable compared to a year ago. The company is focusing on expanding the combo cataract segment and the stand-alone market opportunity. They feel confident about returning to growth in 2026. For Interventional Dry Eye, the guidance is cautious, with $0.7 million revenue in Q4 being a critical milestone. The company has not assumed additional market access wins in the guidance but is focused on market access initiatives for 2026.
Q:What are you assuming for underlying market growth in Interventional Glaucoma, and is the ASP for dry eye sustainable?
A:The glaucoma market is expected to grow in the low to mid-single digits. For dry eye, the ASP reflects a mix of Smart Lids and Smart Hub sold, but specific ASP information is not provided. The mix of products should be considered when modeling revenue.
Q:How do you see the standalone glaucoma market evolving, and what are the obstacles to its growth?
A:The standalone glaucoma market is being activated through targeted investments and education. The company is modeling its activation strategy after cataract surgery workflows. Currently, the MIGS market is about 90% combo cataract and 10% standalone, but Sight Sciences expects its mix to shift with dedicated investments. Obstacles include the time required to develop significant markets and the need to convert patients from eye drops to procedural interventions.
Q:How are you balancing operating expenses with growth opportunities, particularly in dry eye?
A:The company is focusing investments on commercial infrastructure for Interventional Dry Eye, particularly in the two MAC areas. They aim to maintain financial discipline while fueling growth. The early traction in dry eye validates the investments, and the team is expected to grow as reimbursement wins increase.
Q:What is the revenue opportunity for dry eye in the two MACs, and what constraints are you facing?
A:The two MACs cover 10.4 million lives, with an estimated 700,000 patients having moderate to severe MGE. The revenue opportunity is significant, but the main constraint is the company's commercial infrastructure and resources to activate accounts and set up practices. Guidance is prudent, reflecting these constraints.
Q:What is the peak sales potential of TearCare, and how does the company view the market opportunity?
A:The dry eye market is large, with 7-8 million people suffering from moderate to severe MGD. TearCare offers a procedural intervention with proven benefits. The company sees a significant revenue opportunity but did not quantify peak sales. The model is compelling due to the recurring nature of treatments and the broader customer base, including both ophthalmologists and optometrists.
Q:What supports the first-quarter outlook for glaucoma, and are there any headwinds?
A:The first-quarter outlook is supported by stable market conditions, but storms across the U.S. in January and February have been a headwind. No other significant issues were noted.
Q:What is the status of conversations with other MACs and commercial payers for dry eye reimbursement?
A:Conversations with other MACs are progressing, and the company expects more MACs to establish fee schedules this year. The strong clinical and economic data, along with demand from constituents, is creating pressure for other MACs to act. Timing is uncertain but progress is being made.
Q:What is the company's expectation for the new goniotomy codes effective January 2028?
A:The new codes will split goniotomy into adult and pediatric categories. The company expects the adult goniotomy valuation to decrease, which could pressure utilization. However, this may benefit OMNI, as it performs both canaloplasty and goniotomy, potentially making it a more attractive option.
Q:Is the selling approach for dry eye different for ophthalmologists versus optometrists?
A:Currently, the focus is on early visionary accounts, many of which are existing OMNI customers. The selling approach may evolve as coverage density increases, but there is synergy with ophthalmology practices that already have experience with Sight Sciences.
Q:Why was the ordering facility count for glaucoma down sequentially, and is there any pricing benefit from new products?
A:The sequential decline in ordering facility count was due to a strong Q3 in 2025. Growth is expected from reengaging accounts and adding new ones. Pricing benefits from Edge were seen in 2025, but no specific uplift from the upcoming Ultra product is included in the guidance.
Q:Review of Unclear Management Responses
A:Management avoided providing specific ASP information for dry eye products, citing the mix of products sold. They also did not quantify the peak sales potential of TearCare, despite acknowledging the large market opportunity. Additionally, they did not provide exact timing or details on which MACs would establish fee schedules next for dry eye reimbursement. For the new goniotomy codes, they expressed hope for fair valuation but did not provide a clear expectation of the financial impact.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Co Founder
Coast
Director Trip
Dry Eye
Eye Revenues
Eye focus
Eye investment
Eye practice
Eye procedure
Eye reimbursement
Eye team
Eye treatment
Glaucoma Interventional
Glaucoma cause
Glaucoma closing
Glaucoma evaluation
Glaucoma milestone
Glaucoma share
Instructions conference
Interventional Dry
Interventional Glaucoma
MAC Novitas
OMNI
business
code
commercialization
customer engagement
discipline
evaluation workflow
eye Interventional
eye disease
fee schedule
glaucoma treatment
headwind
model
provider engagement
technology team
SGHT Transcript
Sight Sciences, Inc. (SGHT) Q4 2025 Earnings Call Transcript
Positive3-4
The earnings call highlights several positive developments: raised revenue guidance, reduced operating expenses, and significant market opportunities in the dry eye segment. Despite some cautious guidance and uncertainties in reimbursement and market access, the company's strategic focus and expected cost savings position it for growth. The Q&A session supports this with a generally positive sentiment from analysts, despite some vague responses from management. Overall, the positive aspects outweigh the negative, leading to a positive stock price outlook over the next two weeks.
Sight Sciences, Inc. (SGHT) Q3 2025 Earnings Call Transcript
Positive11-6
The company has shown improved financial performance with reduced operating expenses and net loss. Raised revenue guidance and strategic focus on TearCare's growth potential indicate optimism. Despite some uncertainties in the Q&A, the engagement and expansion plans for TearCare and the MIGS market suggest positive sentiment. The market's reaction is likely to be positive, considering the strategic initiatives and financial improvements.
Sight Sciences, Inc. (SGHT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Neutral9-10
Sight Sciences, Inc. (SGHT) Q2 2025 Earnings Call Transcript
Unknown8-8
The earnings call reveals mixed signals: the company reports declining dry eye revenue and gross margins, alongside a net loss. However, they also demonstrate strong performance in the Surgical Glaucoma segment, reduced operating expenses, and positive cash flow. The Q&A highlights confidence in reimbursement for TearCare and market share gains in MIGS, but uncertainties in reimbursement timing and competitive dynamics persist. These factors, coupled with stable guidance, suggest a neutral stock price movement over the next two weeks.
SGHT Slides
SGHT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
